Elucidation of the molecular mechanism and the efficacy in vivo of a novel 1,4-benzoquinone that inhibits 5-lipoxygenase

British Journal of Pharmacology

Volumn 171, Issue 9, 2014, Pages 2399-2412

  Schaible, A M ^a   Filosa, R ^b   Temml, V ^c   Krauth, V ^a   Matteis, M ^d   Peduto, A ^b   Bruno, F ^b   Luderer, S ^e   Roviezzo, F ^f   Di Mola, A ^b   De Rosa, M ^d   D'Agostino, B ^d   Weinigel, C ^g   Barz, D ^g   Koeberle, A ^a   Pergola, C ^a   Schuster, D ^c   Werz, Oliver ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b UNIVERSITY OF SALERNO   (Italy)

^c UNIVERSITY OF INNSBRUCK   (Austria)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e UNIVERSITY OF TÜBINGEN   (Germany)

^f UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^g JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

1,4 benzoquinone; 5 lipoxygenase; inflammation; leukocytes; leukotriene

Indexed keywords

1,4 BENZOQUINONE DERIVATIVE; 3 [(DECAHYDRONAPHTHALEN 6 YL)METHYL] 2,5 DIHYDROXYCYCLOHEXA 2,5 DIENE 1,4 DIONE; ANTIINFLAMMATORY AGENT; ARACHIDONATE 12 LIPOXYGENASE; ARACHIDONATE 15 LIPOXYGENASE; ARACHIDONATE 5 LIPOXYGENASE; CELL PROTEIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; HYDROGEN; HYDROQUINONE; ICOSANOID; INDOMETACIN; PROSTAGLANDIN E SYNTHASE; PROSTAGLANDIN E2 SYNTHASE 1; PROTEIN PLA2; UNCLASSIFIED DRUG; BENZOQUINONE; BENZOQUINONE DERIVATIVE; LIPOXYGENASE INHIBITOR;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BIOSYNTHESIS; BLOOD CELL; CELL STRESS; CONTROLLED STUDY; CYTOSOL; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME STRUCTURE; ENZYME SUBSTRATE COMPLEX; FATTY ACID SYNTHESIS; HUMAN; HUMAN CELL; HYDROGEN BOND; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LEUKOCYTE; MALE; MOLECULAR DOCKING; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; CHEMISTRY; EDEMA; METABOLISM; PROCEDURES; PROTEIN SECONDARY STRUCTURE; SHEEP; TREATMENT OUTCOME;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BENZOQUINONES; EDEMA; HUMANS; LIPOXYGENASE INHIBITORS; MALE; MICE; MOLECULAR DOCKING SIMULATION; PROTEIN STRUCTURE, SECONDARY; SHEEP; TREATMENT OUTCOME;

EID: 84898634905     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12592     Document Type: Article

References (51)

1. Albert D, Zundorf I, Dingermann T, Muller WE, Steinhilber D, Werz O, (2002). Hyperforin is a dual inhibitor of cyclooxygenase-1 and 5-lipoxygenase. Biochem Pharmacol 64: 1767-1775. (Pubitemid 35355728)
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, Peters JA, Harmar AJ, and CGTP Collaborators (2013) the Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol 170: 1797-1867.
3. Back M, Dahlen SE, Drazen JM, Evans JF, Serhan CN, Shimizu T, et al. (2011). International union of basic and clinical pharmacology. LXXXIV: leukotriene receptor nomenclature, distribution, and pathophysiological functions. Pharmacol Rev 63: 539-584.
4. Bain G, King CD, Schaab K, Rewolinski M, Norris V, Ambery C, et al. (2013). Pharmacodynamics, pharmacokinetics and safety of GSK2190915, a novel oral anti-inflammatory 5-lipoxygenase-activating protein inhibitor. Br J Clin Pharmacol 75: 779-790.
5. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, et al. (2000) the protein data bank. Nucleic Acids Res 281: 235-242. (Pubitemid 30047768)
6. Blois MS, (1958). Antioxidant determinations by the use of a stable free radical. Nature 181: 1199-1200.
7. Carter GW, Young PR, Albert DH, Bouska J, Dyer R, Bell RL, et al. (1991). 5-Lipoxygenase inhibitory activity of zileuton. J Pharmacol Exp Ther 256: 929-937.
8. Czapski GA, Czubowicz K, Strosznajder RP, (2012). Evaluation of the antioxidative properties of lipoxygenase inhibitors. Pharmacol Rep 64: 1179-1188.
9. Dandawate PR, Vyas AC, Padhye SB, Singh MW, Baruah JB, (2010). Perspectives on medicinal properties of benzoquinone compounds. Mini Rev Med Chem 10: 436-454.
10. 2. Prostaglandins 30: 769-789. (Pubitemid 16199279)
11. Evans JF, Ferguson AD, Mosley RT, Hutchinson JH, (2008). What's all the FLAP about?: 5-lipoxygenase-activating protein inhibitors for inflammatory diseases. Trends Pharmacol Sci 29: 72-78.
12. Feisst C, Pergola C, Rakonjac M, Rossi A, Koeberle A, Dodt G, et al. (2009). Hyperforin is a novel type of 5-lipoxygenase inhibitor with high efficacy in vivo. Cell Mol Life Sci 66: 2759-2771.
13. Filosa R, Peduto A, Aparoy P, Schaible AM, Luderer S, Krauth V, et al. (2013). Discovery and biological evaluation of novel 1,4-benzoquinone and related resorcinol derivatives that inhibit 5-lipoxygenase. Eur J Med Chem 67: 269-279.
14. Fischer L, Steinhilber D, Werz O, (2004). Molecular pharmacological profile of the nonredox-type 5-lipoxygenase inhibitor CJ-13610. Br J Pharmacol 142: 861-868. (Pubitemid 39004096)
15. Ford-Hutchinson AW, Gresser M, Young RN, (1994). 5-Lipoxygenase. Annu Rev Biochem 63: 383-417. (Pubitemid 24218638)
16. Gilbert NC, Bartlett SG, Waight MT, Neau DB, Boeglin WE, Brash AR, et al. (2011) the structure of human 5-lipoxygenase. Science 331: 217-219.
17. GOLD 5.01 (2012) the Cambridge Crystallographic Data Centre, Cambridge, UK. Available at: http://www.ccdc.cam.ac.uk (accessed 11/3/2014).
18. Hoffmann M, Lopez JJ, Pergola C, Feisst C, Pawelczik S, Jakobsson PJ, et al. (2010). Hyperforin induces Ca(2+)-independent arachidonic acid release in human platelets by facilitating cytosolic phospholipase A(2) activation through select phospholipid interactions. Biochim Biophys Acta 1801: 462-472.
19. Hofmann B, Rodl CB, Kahnt AS, Maier TJ, Michel AA, Hoffmann M, et al. (2012). Molecular pharmacological profile of a novel thiazolinone-based direct and selective 5-lipoxygenase inhibitor. Br J Pharmacol 165: 2304-2313.
20. Israf DA, Tham CL, Syahida A, Lajis NH, Sulaiman MR, Mohamad AS, et al. (2010). Atrovirinone inhibits proinflammatory mediator synthesis through disruption of NF-kappaB nuclear translocation and MAPK phosphorylation in the murine monocytic macrophage RAW 264.7. Phytomedicine 17: 732-739.
21. Jones G, Willett P, Glen RC, Leach AR, Taylor R, (1997). Development and validation of a genetic algorithm for flexible docking. J Mol Biol 267: 727-748. (Pubitemid 27170693)
22. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: Reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
23. Koeberle A, Siemoneit U, Buhring U, Northoff H, Laufer S, Albrecht W, et al. (2008). Licofelone suppresses prostaglandin E2 formation by interference with the inducible microsomal prostaglandin E2 synthase-1. J Pharmacol Exp Ther 326: 975-982.
24. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
25. Nakadate T, Yamamoto S, Aizu E, Kato R, (1985). Inhibition of mouse epidermal 12-lipoxygenase by 2,3,4-trimethyl-6-(12-hydroxy-5,10-dodecadiynyl)-1, 4-benzoquinon e (AA861). J Pharm Pharmacol 37: 71-73. (Pubitemid 15199341)
26. Ohkawa S, Terao T, Murakami M, Matsumoto T, Goto G, (1991). Reduction of 2,3,5-trimethyl-6-(3-pyridylmethyl)-1,4-benzoquinone by PB-3c cells and biological activity of its hydroquinone. Chem Pharm Bull (Tokyo) 39: 917-921.
27. Ohuchi K, Watanabe M, Taniguchi J, Tsurufuji S, Levine L, (1983). Inhibition by AA861 of prostaglandin E2 production by activated peritoneal macrophages of rat. Prostaglandins Leukot Med 12: 175-177. (Pubitemid 14231049)
28. OMEGA version 2.2.1. (2007). OpenEye scientific software, I., Santa Fe, NM, USA. Available at: http://www.eyesopen.com (accessed 11/3/2014).
29. Pergola C, Werz O, (2010). 5-Lipoxygenase inhibitors: a review of recent developments and patents. Expert Opin Ther Pat 20: 355-375.
30. Pergola C, Dodt G, Rossi A, Neunhoeffer E, Lawrenz B, Northoff H, et al. (2008). ERK-mediated regulation of leukotriene biosynthesis by androgens: a molecular basis for gender differences in inflammation and asthma. Proc Natl Acad Sci U S A 105: 19881-19886.
31. Pergola C, Rogge A, Dodt G, Northoff H, Weinigel C, Barz D, et al. (2011). Testosterone suppresses phospholipase D, causing sex differences in leukotriene biosynthesis in human monocytes. FASEB J 25: 3377-3387.
32. Pergola C, Jazzar B, Rossi A, Northoff H, Hamburger M, Sautebin L, et al. (2012). On the inhibition of 5-lipoxygenase product formation by tryptanthrin: mechanistic studies and efficacy in vivo. Br J Pharmacol 165: 765-776.
33. Peters-Golden M, Henderson WR Jr, (2007). Leukotrienes. N Engl J Med 357: 1841-1854.
34. Petronzi C, Filosa R, Peduto A, Monti MC, Margarucci L, Massa A, et al. (2011). Structure-based design, synthesis and preliminary anti-inflammatory activity of bolinaquinone analogues. Eur J Med Chem 46: 488-496.
35. Petronzi C, Festa M, Peduto A, Castellano M, Marinello J, Massa A, et al. (2013). Cyclohexa-2,5-diene-1,4-dione-based antiproliferative agents: design, synthesis, and cytotoxic evaluation. J Exp Clin Cancer Res 32: 24. doi: 10.1186/1756-9966-32-24.
36. Poeckel D, Niedermeyer TH, Pham HT, Mikolasch A, Mundt S, Lindequist U, et al. (2006). Inhibition of human 5-lipoxygenase and anti-neoplastic effects by 2-amino-1,4-benzoquinones. Med Chem 2: 591-595. (Pubitemid 44752493)
37. Rackham A, Ford-Hutchinson AW, (1983). Inflammation and pain sensitivity: effects of leukotrienes D4, B4 and prostaglandin E1 in the rat paw. Prostaglandins 25: 193-203. (Pubitemid 13047711)
38. Radmark O, Werz O, Steinhilber D, Samuelsson B, (2007). 5-Lipoxygenase: regulation of expression and enzyme activity. Trends Biochem Sci 32: 332-341. (Pubitemid 47021417)
39. Reddanna P, Rao MK, Reddy CC, (1985). Inhibition of 5-lipoxygenase by vitamin E. FEBS Lett 193: 39-43. (Pubitemid 16170821)
40. Schaible AM, Traber H, Temml V, Noha SM, Filosa R, Peduto A, et al. (2013). Potent inhibition of human 5-lipoxygenase and microsomal prostaglandin E synthase-1 by the anti-carcinogenic and anti-inflammatory agent embelin. Biochem Pharmacol 86: 476-486.
41. Syahida A, Israf DA, Permana D, Lajis NH, Khozirah S, Afiza AW, et al. (2006). Atrovirinone inhibits pro-inflammatory mediator release from murine macrophages and human whole blood. Immunol Cell Biol 84: 250-258.
42. Tardif JC, L'Allier PL, Ibrahim R, Gregoire JC, Nozza A, Cossette M, et al. (2010). Treatment with 5-lipoxygenase inhibitor VIA-2291 (Atreleuton) in patients with recent acute coronary syndrome. Circ Cardiovasc Imaging 3: 298-307.
43. Wasfi YS, Villaran C, de Tilleghem CLB, Smugar SS, Hanley WD, Reiss TF, et al. (2012) the efficacy and tolerability of MK-0633, a 5-lipoxygenase inhibitor, in chronic asthma. Respir Med 106: 34-46.
44. Werz O, (2002). 5-Lipoxygenase: cellular biology and molecular pharmacology. Curr Drug Targets Inflamm Allergy 1: 23-44.
45. Werz O, (2007). Inhibition of 5-lipoxygenase product synthesis by natural compounds of plant origin. Planta Med 73: 1331-1357. (Pubitemid 350084452)
46. Werz O, Steinhilber D, (2006) therapeutic options for 5-lipoxygenase inhibitors. Pharmacol Ther 112: 701-718. (Pubitemid 44592614)
47. Werz O, Szellas D, Henseler M, Steinhilber D, (1998). Nonredox 5-lipoxygenase inhibitors require glutathione peroxidase for efficient inhibition of 5-lipoxygenase activity. Mol Pharmacol 54: 445-451. (Pubitemid 28368835)
48. Wolber G, Bendix F, Ibis G, Kosara R, Seidel T, Dornhofer A, (2009) LigandScout, 3.0. Inte:Ligand GmbH: Vienna, Austria. Available at: http://www.inteligand.com (accessed 11/3/2014).
49. Wurm G, Schwandt S, (2003). Methylated 2-aryl-1,4-naphtoquinone derivatives with diminished antioxidative activity. Pharmazie 58: 531-538. (Pubitemid 37012231)
50. Xu GL, Liu F, Ao GZ, He SY, Ju M, Zhao Y, et al. (2009). Anti-inflammatory effects and gastrointestinal safety of NNU-hdpa, a novel dual COX/5-LOX inhibitor. Eur J Pharmacol 611: 100-106.
51. Yoshimoto T, Yokoyama C, Ochi K, Yamamoto S, Maki Y, Ashida Y, et al. (1982). 2,3,5-Trimethyl-6-(12-hydroxy-5,10-dodecadiynyl)-1,4-benzoquinone (AA861), a selective inhibitor of the 5-lipoxygenase reaction and the biosynthesis of slow-reacting substance of anaphylaxis. Biochim Biophys Acta 713: 470-473. (Pubitemid 13222960)